Flecainide Versus Procainamide in Electrophysiological Study in Patients With Syncope and Wide QRS Duration

Ivo Roca-Luque*, Jaume Francisco-Pasqual, Gerard Oristrell, Julián Rodríguez-García, Alba Santos-Ortega, Gabriel Martin-Sanchez, Nuria Rivas-Gandara, Jordi Perez-Rodon, Ignacio Ferreira-Gonzalez, David García-Dorado, Angel Moya-Mitjans

*Autor corresponent d’aquest treball

Producció científica: Contribució a una revistaArticleRecercaAvaluat per experts

14 Cites (Scopus)

Resum

Objectives: This study sought to compare the differences between procainamide and flecainide to stress the His-Purkinje system during electrophysiological study (EPS) in patients with syncope and bundle branch block (BBB). Background: Patients with syncope and BBB are at risk of developing atrioventricular block. EPS is recommended including class I drug challenge to unmask His-Purkinje disease in cases with baseline normal His-ventricular interval. There is little data on differences between different class I drugs. Methods: This was a prospective study of all consecutive patients undergoing EPS for syncope and BBB at a single center (January 1, 2012 to June 30, 2017). Of those patients with negative baseline EPS, 2 cohorts were compared: group A (historical cohort: procainamide) and group B (flecainide). Results: During the study, 271 patients (age 73.9 ± 12.1 years, 64.9% male, QRS duration: 139.4 ± 13.9 ms) underwent EPS. In 166, baseline EPS was negative and class I drug challenge was performed (90 procainamide, 76 flecainide). The final value and percentage increase in the His-ventricular interval (76 ± 16 ms vs. 64 ± 10 ms and 22.5 ± 6.2% vs. 11.8 ± 5.3%; p < 0.001) and diagnostic yield (14.5% vs. 7.8%, p = 0.04) were higher with flecainide. No differences were found in baseline characteristics. During follow-up (25.8 ± 6.3 months), 39 patients (24.8%) with negative EPS (19.2% with flecainide vs. 30.1% with procainamide: relative risk: 5.1; 95% confidence interval: 2.6 to 10.2; p < 0. 001) received a pacemaker. Conclusions: Flecainide has a higher diagnostic yield than does procainamide in patients with BBB, syncope, and negative baseline EPS due to a greater increase of the His-ventricular interval. Additionally, there is a lesser need for pacemaker implantation in patients in whom the class I drug test using flecainide was negative.
Idioma originalEnglish
Pàgines (de-a)212-219
Nombre de pàgines8
RevistaJACC: Clinical Electrophysiology
Volum5
Número2
DOIs
Estat de la publicacióPublicada - de febr. 2019

Fingerprint

Navegar pels temes de recerca de 'Flecainide Versus Procainamide in Electrophysiological Study in Patients With Syncope and Wide QRS Duration'. Junts formen un fingerprint únic.

Com citar-ho